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Abstract
Background: Although chemotherapy represents a predominant anti-cancer therapeutic modality, drug treatment
efficacy is often limited due to the development of resistant tumor cells. The pregnane X receptor (PXR) affects
chemotherapeutic effects by regulating targets involved in drug metabolism and transportation, but the regulatory
mechanism is poorly understood.
Methods: Oxaliplatin (L-OHP) content in tumor cells was analyzed by mass cytometry. The roles of PXR on cancer
cell proliferation, apoptosis and tumor growth with L-OHP-treated were investigated by MTS, colony formation, flow
cytometry and xenograft tumor assays. Luciferase reporter, Chromatin-immunoprecipitation and Site-directed
mutagenesis were evaluated the mechanisms. The PXR and multidrug resistance-related protein 3 (MRP3)
expressions were examined by western blot, RT-PCR or immunohistochemistry of TMA. Kaplan-Meier and Cox
regression were adopted to analyze the prognostic value of PXR in colorectal cancer (CRC).
Results: PXR over-expression significantly increased oxaliplatin (L-OHP) transport capacity with a reduction of its
content and repressed the effects of L-OHP on tumour cell proliferation and apoptosis. Conversely, PXR knockdown
augments L-OHP-mediated cellular proliferation and apoptosis. Moreover, PXR significantly reduced the therapeutic
effects of L-OHP on tumor growth in nude mice. Further studies indicated a positive correlation between PXR and
MRP3 expression and this finding was confirmed in two independent cohorts. Significantly increased MRP3
expression was also found in PXR over-expressing cell lines. Mechanistically, PXR could directly bind to the MRP3
promoter, activating its transcription. The PXR binding sites were determined to be at -796 to -782bp
(CTGAAGCAGAGGGAA) and the key binding sites were the “AGGGA” (-787 to -783bp) on the MRP3 promoter.
Accordingly, blockade of MRP3 diminishes the effects on drug resistance of PXR. In addition, PXR expression is
significantly associated with poor overall survival and represents an unfavorable and independent factor for male or
stage I + II CRC patient prognosis.
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Conclusions: PXR is a potential biomarker for predicting outcome and activates MRP3 transcription by directly
binding to its promoter resulting in an increased L-OHP efflux capacity, and resistance to L-OHP or platinum drugs
in CRC. Our work reveals a novel and unique mechanism of drug resistance in CRC.
Keywords: Colorectal cancer, Chemotherapy resistance, PXR, MRP3, Transcriptional regulation, Overall survival
Background
Colorectal cancer (CRC), a malignancy of the gastrointes-
tinal tract, is the third most common tumor worldwide [1].
CRC patient outcomes have significantly improved due to
the use of novel treatment modalities and complex treat-
ment strategies, including optimized surgery, adjuvant
chemotherapy and novel targeted biological agents. At an
early stage, CRC is potentially curable by surgery followed
by chemotherapy [2]. However, approximately 25% of CRC
patients present with metastatic disease at diagnosis and
are unlikely to undergo curative surgical resection, and
many patients with metastatic disease will relapse after po-
tentially curative resections [3, 4]. For these patients, sys-
temic chemotherapy is most often the treatment of choice
for increasing survival and improving quality of life [5, 6].
Thus, chemotherapy is one of the most important treat-
ments for malignancies in humans [7]. Previous studies
have revealed that the response rate after initial chemother-
apy treatment is approximately 50% for CRC patients [8, 9].
However, only 10% of CRC patients respond to secondary
treatments [8]. These data suggest that there is a high de-
gree of resistance to current chemotherapies.
The pregnane X receptor (PXR/NR1I2) is a ligand-
activated transcription factor belonging to the nuclear hor-
mone receptor (NR) superfamily [10]. PXR is expressed in
many normal human tissues, including ovary, small intes-
tine, colon, liver, breast, heart, and prostate [11]. Further-
more, increased PXR expression has been reported in
various tumors, such as breast, ovarian, colon and endomet-
rial cancers [12–17]. Further studies have shown that PXR
plays an important role in the development of resistance to
certain chemotherapeutic cancer treatments [18–22]. PXR
activates many drug-metabolizing enzymes and drug trans-
porters, resulting in altered drug clearance [23]. Our previ-
ous study showed that the mRNA expression of MRP3
significantly correlates with PXR expression in CRCs, sug-
gesting that MRP3 might be involved in PXR-mediated che-
motherapeutic resistance [16]. However, the specific role
and precise molecular mechanism of PXR- and MRP3-
mediated chemotherapeutic resistance remain unclear.
In the present study, we demonstrated that PXR sig-
nificantly reduced the amount of oxaliplatin (L-OHP) in
tumor cells, and prevented L-OHP-mediated inhibition
of cellular proliferation and induction of apoptosis. Our
nude mouse model showed that PXR reduced the effi-
cacy of L-OHP treatment on tumor growth. Further
analysis revealed a positive correlation between MRP3
and PXR expression (P = 0.0023), which was confirmed
in two independent cohorts from The Cancer Genome
Atlas (TCGA) database. We also detected increased
MRP3 expression in PXR over-expressing cell lines.
Moreover, luciferase reporter, ChIP and site-directed
mutagenesis assays demonstrated that PXR could dir-
ectly bind to the MRP3 promoter, and that the key bind-
ing site were located at -796 to -782bp on the MRP3
promoter. Further investigations showed that PXR ex-
pression was associated with poor prognosis and was an
independent prognostic factor in CRC. Our data reveal
that PXR can transcriptionally activate MRP3 expression
by directly binding to its promoter, which increases drug




A total of 93 colorectal cancerous and 87 corresponding
noncancerous tissues were obtained from the Southwest
Hospital in Chongqing, China. This study was approved
by the ethics committee of Southwest Hospital. In-
formed consent was obtained from all recruited patients.
Tissue microarray generation and immunohistochemical
analysis
Noncancerous adjacent tissues were compared with
normal tissue, stained with haematoxylin-eosin and
reviewed by at least 2 pathologists. The tissue micro-
array (TMA) containing tissues from 93 tumors with
87 pairs of tumor and matched peritumoural tissues,
was constructed (in collaboration with Shanghai Bio-
chip Company Ltd, Shanghai, China) as previously
described [24].
Immunohistochemistry (IHC) was performed using
PXR and MRP3 antibodies (both 1:200; both from Santa
Cruz Biotechnology; sc-48403 and sc-5774). Tumor cell
staining was considered positive when immunoreactivity
was greater than or equal to 10%. Positive staining was
divided into 5 categories, and staining intensity was
graded according to 4 levels as previously described [25].
The expression levels were defined by the sum of posi-
tive staining and intensity.
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The construction and transfection of expression and
siRNA vectors for PXR
Expression and siRNA vectors for PXR were constructed
and transfected as previously described [26]. The stably
PXR-transfected cells were selected using G418 (Calbio-
chem, La Jolla, CA, USA). Cell clones were obtained
using the cylinder method.
RT-PCR and western blotting (WB) analysis
The mRNA expression analysis was performed using
RT-PCR. Series PCR assays with different cycle numbers
were performed to determine the linear phase of amplifi-
cation. Based on the pilot experiments, the appropriate
cycles were chosen. The primers are listed in Additional
file 1: Table S1.
Sixty micrograms of protein was resolved by 10–15%
sodium dodecyl sulphate- polyacrylamide gel electro-
phoresis and transferred onto polyvinylidene difluoride
membranes (Millipore Corporation, Bedford, MA, USA).
After blocking, the membranes were incubated with pri-
mary antibodies overnight at 4 °C. The proteins were de-
tected by chemiluminescence (Pierce, Rockford, IL,
USA) after incubation with secondary antibodies. The
probed membranes were stripped and incubated with β-
actin monoclonal antibody (1:1200; Sigma). The primary
antibodies used were PXR mouse monoclonal antibody
(1:1000, Santa Cruz Biotechnology, sc-48403) and MRP3
goat polyclonal antibody (1:800; Santa Cruz Biotechnol-
ogy, sc-5774). The secondary antibodies used were
horseradish peroxidase-conjugated anti-mouse and anti-
goat antibodies (both 1:2000, Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA).
Oxaliplatin drug treatment
For L-OHP content measurement, tumor cells were
treated for 2 h at a concentration of 20mmol/L L-OHP
(Hengrui Medicine, Lianyungang, Jiangsu Province,
China); For the functional experiments in vitro, tumor
cells were exposed for 24 h to 20 mmol/L L-OHP. The
culture medium was replaced on a daily. For the tumor
formation in vivo, the nude mice were injected once
every 3 days with 5 mg of L-OHP (dissolved in normal
saline)/kg body weight. Controls were treated with the
same volume of normal saline.
Measurement of L-OHP content in tumour cells by mass
cytometry
The transfected, L-OHP-treated tumor cells were ana-
lyzed using a CyTOF1 mass cytometer (DVS Sciences,
Richmond Hill, Ontario, Canada). The instrument set-
tings and initial post-processing parameters were set as
previously described [27–29]. Cells were measured at ap-
proximately 600 cells per second. Noise reduction was
activated, and cell extraction parameters were as follows:
cell length range was set from 15- to- 65 pushes, and
the lower convolution threshold was set to 15.
Colony-formation and MTS assay
HCT116 and LOVO cells were plated in 12-well plates at
3 × 105 cells per well. After culturing for 24 h, the cells
were transfected with PXR or vector plasmids. After 48h
of transfection, the cells were collected, diluted 1:5, plated
in 12-well plates and selected with 0.8mg/ml of G418 for
14 days to establish stable clones and for subsequent treat-
ment with L-OHP. Surviving colonies were stained by
using Giemsa’s azur eosin methylene blue solution
(Merck, Darmstadt, Germany) and counted. These experi-
ments were performed in triplicate.
HCT116 and LOVO cells were plated in 96-well plates
at 3.5 × 103 cells per well, transfected with PXR or empty
vector plasmids, and treated with L-OHP. For knock-
down, SW480 cells were plated in 96-well plates at 3 ×
103 cells per well, transfected with PXR siRNA or nega-
tive control plasmids, and treated with L-OHP. Cell pro-
liferation was evaluated using the Cell Proliferation
Reagent MTS (CellTiter 96® Aqueous One Solution Cell
Proliferation Assay, Promega) on days 1, 2, and 3. The
assay was carried out in triplicate in three independent
experiments.
Flow cytometry assay
PXR or empty vector-transfected cells (3.5 × 105 cells per
well) were harvested at 48 h post-transfection and L-
OHP treatment, and fixed in 70% ethanol overnight at 4
°C. The cells were stained with propidium iodide (BD
Pharmingen, San Jose, CA, USA). Fifty thousand cells
were sorted by FACSCalibur System (BD Biosciences,
Franklin Lakes, NJ, USA), and cell cycle profiles were
analysed using the ModFit software (Verity Software
House, Topsham, ME, USA). Apoptosis was also
assessed by Annexin V-APC/7-amino-actinomycin D
staining (KeyGEN, Nanjing, China). Briefly, cells were
harvested, washed with phosphate-buffered saline, resus-
pended in 500 μl of binding buffer, mixed with 5 μl of
Annexin V-APC and 5μl of 7-ADD, incubated for 5–15
min in the dark. Fifty thousand cells were analyzed using
a FACSCalibur cytometer. The Annexin V-positive cells
were considered apoptotic cells and analysed using the
ModFit software. The assays were carried out in tripli-
cate in three experiments.
In vivo tumourigenicity
To assess the effects of PXR expression and L-OHP
treatment on tumour formation in vivo, the PXR- or
empty vector-expression stable HCT116 cells were
injected subcutaneously into the right flanks of 6-week-
old male Balb/c nude mice that were subsequently
subjected to L-OHP treatment. Tumor volume was
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calculated as 0.5236 L1 (L2)2 [30]. The developing tu-
mors were observed during the following 5 weeks, after
which the mice were sacrificed. All mouse experiments
were approved by the Institutional Animal Care and
Use Committee of Third Military Medical University,
China.
Site-directed mutagenesis of binding site assay
The site-directed mutagenesis assays were performed as
previous study (26). The binding sites in MRP3 pro-
moter constructs were mutated or deleted using a Quik-
Change Lightning Multi Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) according to the instruc-
tions, and the mutations or deletions were confirmed by
direct DNA sequencing.
Luciferase reporter and chromatin-immunoprecipitation
(ChIP) assay
Cells were seeded in 24-well plates at 3.5 × 104 cells per
well. After an overnight incubation, the cells were trans-
fected with a DNA mixture including pGL3-MRP3
promoter-luciferase, pIRES2-EGFP-PXR or vector, as
well as the internal pRL-TK plasmids. Luciferase activ-
ities were measured at 36 h post-transfection using a
dual-luciferase reporter kit (Promega). Each experiment
was performed in triplicate and repeated three times.
Chromatin-immunoprecipitation (ChIP) analysis was
performed using a ChIP Assay Kit (Cell Signaling Tech-
nology) according to the manufacturer’s protocols. The
immunoprecipitated and input DNA were used as tem-
plates for RT-PCR analysis, and the primers are listed in
Additional file 1: Table S1.
Fig. 1 PXR over-expression decreases L-OHP levels in tumor cells. The transport and uptake of L-OHP in tumor cells were assessed by mass cy-
tometry. L-OHP content in PXR or PXR + RXRA stably transfected tumor cells was reduced compared with that in empty vector stably transfected
tumor cells on average in both HCT116 (a) and LOVO (b) cells. Tumour cells were treated for 2 h with 20 mmol/L oxaliplatin. P + R, PXR + RXRA.
The unit shown is Pt atoms/cell
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Statistical analyses
Statistical analyses were performed using SPSS 13.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). The results are
expressed as the mean ± standard deviation (s.d.). The
data were analysed by Student’s t and chi-square (2-sided)
tests. Patient clinical and pathological characteristics were
compared by Pearson χ2 test. Overall survival (OS) was
calculated according to Kaplan-Meier and Cox regression.
The p values less than 0.05 were considered significant.
Results
PXR decreases oxaliplatin (L-OHP) levels in tumor cells
To determine the role of PXR in L-OHP-treated tumor
cells, L-OHP transport and uptake were assessed by mass
cytometry in tumor cells transfected with PXR or empty
vector, as well as in those transfected with PXR +RXRA,
which generally forms a heterodimer that transcriptionally
activates target genes. Our results revealed that the L-OHP
content in tumor cells stably transfected with PXR or PXR
+RXRA was on average significantly lower than that in
tumor cells transfected with empty vector in both HCT116
and LOVO cells (Fig. 1a, b). These results showed that PXR
notably increased the L-OHP efflux capacity of tumor cells,
thereby reducing intracellular L-OHP content.
PXR prevents L-OHP-mediated inhibition of cancer cell
proliferation and apoptosis
To explore the functional roles of reduced L-OHP con-
tent, we performed cell proliferation assays in L-OHP-
treated PXR over-expressing cells. The MTS data and
colony-formation assays indicated that PXR prevented
the L-OHP-mediated suppression of tumor cell prolifer-
ation (Fig. 2a-c, Additional file 1: Table S2). To exclude
the possible direct role of PXR over-expression, the data
Fig. 2 PXR prevents L-OHP-mediated tumor cell growth inhibition and induction of apoptosis. a PXR and empty vector control transfectants were
identified by RT–PCR and WB in HCT116. Abundant PXR was detected in PXR transfectants but not in empty vector transfectants. β-actin was used
as an internal control. b MTS assays were used to examine the effects of PXR on L-OHP-mediated suppression of tumor cell proliferation. Cell viability was
evaluated in triplicate. *P< 0.05; **P< 0.01. c The effects of PXR on L-OHP-mediated cell growth were further confirmed using colony-formation assays. The
colonies were counted. The error bars indicate the s.d. (n = 3), **P < 0.01. d The effects of PXR on L-OHP-induced cellular apoptosis were
detected by propidium iodide flow cytometric assessment of the sub-G1 fraction. The error bars indicate the s.d. (n = 3). e The effects of
PXR on L-OHP-induced cellular apoptosis were detected by Annexin V-APC/7-amino-actinomycin D flow cytometry. The error bars indicate the s.d.
(n = 3). f PXR knockdown was confirmed by RT–PCR and WB in SW480 cells. β-actin was used as an internal control. g An MTS assay was performed to
assess cell proliferation after PXR knockdown and treatment with L-OHP. Cell viability was evaluated in triplicate. *P < 0.05; **P < 0.01. h The effects of
PXR knockdown on L-OHP-induced cellular apoptosis were detected by propidium iodide flow cytometric assessment of the sub-G1 fraction. The error
bars indicate the s.d. (n = 3). i Effect of PXR knockdown on L-OHP-induced cell apoptosis was detected by Annexin V-APC/7-amino-actinomycin D flow
cytometry. The error bars indicate the s.d. (n = 3)
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of MTS assay presented also include groups without L-
OHP treatment (Fig. 2b). To further examine the effects
of PXR over-expression on the L-OHP-mediated inhib-
ition of cellular proliferation, we measured the percent-
age of sub-G1 phase cells and also performed Annexin
V-APC/7-amino-actinomycin D staining followed by
flow cytometric analysis. The PXR-transfected tumor
cells exhibited a significantly reduced percentage of sub-
G1/apoptotic cells as compared with empty vector-
transfected cells that were treated with L-OHP (Fig. 2d).
The double staining analysis revealed that PXR over-
expression decreased the percentage of early- and late-
stage apoptotic cells after L-OHP treatment (Fig. 2e).
These results demonstrated that PXR over-expression
promoted tumor cell proliferation and inhibited tumor
cell apoptosis during L-OHP treatment.
To further demonstrate that PXR expression can influ-
ence tumor cell proliferation and apoptosis during L-
OHP treatment, we constructed a PXR-knockdown
SW480 cell model (Fig. 2f ). Cell proliferation and flow
cytometry assays revealed that PXR knockdown inhib-
ited tumor cell proliferation and promoted apoptosis
after L-OHP treatment (Fig. 2g-i). The data of MTS
assay presented also include groups without L-OHP
treatment (Fig. 2g). These results further demonstrated
that PXR promoted tumor cell proliferation and inhib-
ited L-OHP-induced tumor cell apoptosis.
PXR reduces the curative effect of L-OHP on tumor
growth in nude mice
Our experiments demonstrated that PXR can promote
tumor cell proliferation and inhibit tumor cell apoptosis
during L-OHP treatment in vitro. To test this conclusion
in vivo, we assessed tumourigenicity in a nude mouse
model of stable PXR-expressing cells and L-OHP treat-
ment. Tumor volumes were significantly larger in L-OHP-
treated mice injected with PXR-transfected cells compared
with those injected with empty vector-transfected cells
(Fig. 3a, b). PXR over-expression resulted in an increase of
the mean weight of tumors collected at 5 weeks after cell
inoculation (Fig. 3c, d). To exclude the possible direct role
of PXR, the data of tumor volumes and weights from
nude mice were also presented without L-OHP treatment
(Fig. 3e). Collectively, these data indicated that PXR sig-
nificantly reduced the curative effects of L-OHP on tumor
growth.
Fig. 3 PXR reduces the curative effect of L-OHP on tumor growth in nude mice. a, b The tumor growth curve of PXR-expressing cells was compared
with vector-expressing cells after L-OHP treatment. Tumor growth was assessed in nude mice that were subcutaneously injected in the right flank with
5.0 × 106 stable transfectants. Points represent the mean tumor volumes of three independent experiments (n = 3). c, d Tumor weights from the PXR
and vector groups were measured. The results were obtained from three independent experiments. *P < 0.05; **P < 0.01. The error bars indicate the
s.d. (n = 3). e The tumor growth curve and tumor weights of PXR-expressing cells were compared with vector-expressing cells. The results were
obtained from three independent experiments. The error bars indicate the s.d. (n = 3)
Dong et al. Molecular Cancer  (2017) 16:71 Page 6 of 13
PXR positively correlates with MRP3 expression in CRC
To investigate the protein levels of PXR and MRP3 ex-
pression in human CRCs, we performed IHC for PXR
and MRP3 in a TMA containing 93 cancer and 87 para-
carcinoma colorectal tissues. PXR protein levels were
increased in most cancer tissues compared with para-
carcinoma tissues, and the mean expression of PXR in
cancer tissues (8.366) was significantly increased com-
pared with para-carcinoma tissues (3.586) (P < 0.001)
(Fig. 4a, b). MRP3 protein levels were also increased in
most cancers compared with para-carcinoma tissues,
and the mean expression of MRP3 in the cancer tissues
(6.361) was significantly increased compared with that of
the para-carcinoma tissues (4.083) (P < 0.001) (Fig. 4a,
b). These results suggested that PXR and MRP3 were
frequently over-expressed in tumor tissues compared
with in adjacent tissues.
To further evaluate whether PXR correlates with
MRP3 expression, we assessed the relationship between
MRP3 and PXR protein expression. Statistical analysis
revealed a significant positive correlation between PXR
and MRP3 protein expression in CRC (Fig. 4c, P =
0.0023), a result that was further confirmed in two in-
dependent cohorts from TCGA database at mRNA
level (Fig. 4d). These results indicated that PXR might
increase platinum drug metabolism, causing resistance
to platinum drugs by up-regulating MRP3 gene
expression.
PXR activates MRP3 transcription by directly binding to
its promoter
To elucidate the molecular mechanism underlying the
PXR-mediated regulation of MRP3, gene expression pro-
filing was performed using stable transfectants. Our data
revealed that MRP3 expression increased with the in-
crease of PXR expression (Fig. 5a). As PXR is a tran-
scription factor, we first analyzed whether it could
directly regulate MRP3 at the transcriptional level. To
test this hypothesis, we performed a luciferase reporter
assay, which revealed that PXR over-expression signifi-
cantly enhanced the activity of the MRP3 promoter
(-2052 to +117bp), suggesting that PXR regulates MRP3
Fig. 4 PXR positively correlates with MRP3 expression in colorectal cancer. a Immunohistochemical analysis of PXR and MRP3 expression was performed
on cancerous and adjacent noncancerous samples. Low levels of PXR and MRP3 expression were observed in noncancerous tissues compared with
cancerous tissues. Scale bars represent 50 μm. Representative samples were shown. b PXR and MRP3 expression levels were analyzed in cancerous and
adjacent noncancerous tissues. PXR and MRP3 expression was higher in cancerous tissues than in adjacent noncancerous tissues. The error bars indicate
the s.d. c A significant positive correlation between PXR and MRP3 expression was detected in colorectal cancer. The scale bars represent 50 μm.
Representative samples were shown. d A significant positive correlation between PXR and MRP3 expression was also observed in two other independent
colorectal cancer cohorts from the TCGA database. Heat map was generated to compare PXR and MRP3 expression in the TCGA colorectal cancer gene
expression dataset (https://genome-cancer.soe.ucsc.edu/proj/site/xena/heatmap/)
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by directly binding to its promoter. To identify the PXR-
binding site(s) within the MRP3 promoter, different re-
gions of the MRP3 promoter (pMRP-Luc-B- ~ E) were
analyzed using luciferase reporter assays. Our results
showed that the key region required for PXR binding
was located between -884 to -620bp of the MRP3 pro-
moter (Fig. 5b-d). This result was confirmed by a ChIP-
PCR assay, and aided by the binding profile database of
Jaspar and ConSite, we determined that the crucial
binding region resides within -796 to -782bp (CTG
AAGCAGAGGGAA) of the MRP3 promoter (Fig. 5e).
To confirm the binding sites in the “CTGAAGCA-
GAGGGAA” region of the MRP3 promoter, two differ-
ent regions of MRP3 promoter between -884 and
-620bp (pMRP-Luc-F and G) were then analyzed using
luciferase reporter assays. The data revealed that the re-
gion containing “CTGAAGCAGAGGGAA” region was
required for PXR binding (Fig. 5f ). To further investi-
gate the key binding sites, constructs with site-directed
mutagenesis of binding sites were generated. When the
PXR-binding sites, ———————AGGGA-(-787 to
-783bp), in MRP3 promoter were mutated or deleted,
the activation was lost (Fig. 5g). These findings demon-
strated that MRP3 was a direct PXR target gene in
CRC.
MRP3 is a key player in PXR mediated drug resistance
To define whether MRP3 was required for PXR medi-
ated drug resistance in CRC, we performed a rescue ex-
periment by knocking down MRP3 in PXR over-
expressed cells followed by testing cellular proliferation,
apoptosis and intracellular L-OHP content. The results
of rescue experiment demonstrated that blockade of
MRP3 by small interfering RNA (siRNA) significantly di-
minished the effect of PXR over-expression on cancer
cell proliferation, apoptosis and intracellular L-OHP
content (Fig. 6a–d). These data indicate that the contri-
bution of MRP3 is very important for PXR mediated
drug resistance in CRC.
Fig. 5 PXR activates MRP3 transcription by directly binding to its promoter. a Ectopic expression of PXR significantly enhances the endogenous
expression of MRP3. PXR and MRP3 expressions were examined by RT-PCR and WB, and β-actin was used as an internal control. b Different regions of the
MRP3 promoter were cloned into a luciferase reporter construct. c, d PXR targets MRP3 directly, and the key PXR binding region is located between -884
to -620bp of the MRP3 promoter as determined by luciferase reporter assays. The results were normalized to internal controls from three experiments. e
ChIP-PCR was performed to identify MRP3 as a PXR target. Jaspar and ConSite predicted the PXR binding sites as located between -796 to -782bp of the
MRP3 promoter. f The key PXR binding region is located between -884 to -754bp of the MRP3 promoter determined by luciferase reporter assays. The
results were normalized to internal controls from three experiments. **P< 0.01. g The effects of PXR on wild-type and mutated/deleted MRP3 promoter
(between -796 to -782bp) activity. Error bars indicate s.d. (n= 3), *, mutated sites; -, deleted sites. **P< 0.01
Dong et al. Molecular Cancer  (2017) 16:71 Page 8 of 13
PXR expression is significantly associated with poor
overall survival in < h2 > CRC patients
To determine the importance of PXR in CRC, the clinical
and prognostic significance of PXR expression were ana-
lyzed. Based on the quantified positive staining of tumor
cells, PXR expression was classified into two groups
around the median score: as high (>median) and low
(≤median). After investigating the association between
PXR expression and the clinicopathological features of
CRC patients, PXR expression was significantly correlated
with patient age (P = 0.011), but not with sex, lymph node
status, histological grade, tumor size and clinical stage
(Additional file 1: Table S3 and Additional file 2).
To investigate the correlation between PXR expres-
sion and survival of CRC patients, we next examined
the contribution of PXR expression to patient OS.
Kaplan-Meier survival analysis revealed a poorer OS in can-
cer patients characterized with high PXR expression com-
pared with patients with low PXR expression (P = 0.013;
Fig. 7a). To avoid bias, PXR expression and other
parameters were examined in a multivariate Cox-regression
analysis. PXR expression was found to be an independent
prognostic factor [hazard ratio (HR) = 1.463, 95% CI 1.049-
2.041, P = 0.025], in addition to age (HR = 1.040, 95% CI
1.000-1.081, P = 0.049), for patient OS (Fig. 7a, Additional
file 1: Table S4 and Additional file 2).
To determine the importance of other clinicopatho-
logical features on the correlation between PXR expres-
sion and OS of cancer patients, we stratified patients by
PXR expression and other clinicopathological features
followed by analysis of survival data. The results re-
vealed that PXR expression was significantly associated
with OS of male patients (univariate, p = 0.044/multi-
variate, p = 0.006) or the patients at clinical stage I + II
(univariate, p = 0.009/multivariate, p = 0.014) (Fig. 7b, c,
Additional file 1: Table S5, Table S6 and Additional file 2).
However, PXR expression was not statistically correlated
with OS of female patients (p = 0.134) or the patients at
clinical stage III + IV (p = 0.247). There are no different
impacts about histological grade on the correlation be-
tween PXR expression and OS. These findings sug-
gested that PXR was an unfavorable and independent
prognostic factor for male or clinical stage I + II CRC
patients.
Fig. 6 MRP3 is a functionally target gene of PXR in drug resistance. a The expression of PXR and MRP3 was analyzed by WB at 48h after
transfecting with MRP3 small interfering RNA (siRNA). The MRP3 siRNA was purchased from Santa Cruz Biotechnology. b Analysis of the effects of
L-OHP on cancer cell proliferation when different PXR and MRP3 expression. Cell numbers were counted every day after treatment for 4 days. c
Analysis of the effects of L-OHP on cancer cell apoptosis when different PXR and MRP3 expression. d The transport and uptake of L-OHP in
tumour cells with different PXR and MRP3 expression were assessed by mass cytometry
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Discussion
In this study, we investigated the molecular mechanisms
of PXR-mediated MRP3 over-expression, which we dem-
onstrate for the first time contributes to chemotherapeutic
resistance in CRC. Our data demonstrated that PXR in-
creased the L-OHP efflux capacity, reducing drug concen-
trations in tumor cells. Functional analysis revealed that
PXR blunted L-OHP-mediated inhibition of cellular
proliferation and inducing of apoptosis. Our nude mouse
experiments showed that PXR reduced the efficacy of
L-OHP treatment on tumor growth. TAM analysis re-
vealed increased expression of PXR and MRP3 in cancer
tissues and a positive correlation between MRP3 and PXR
expression (P = 0.0023), which was further confirmed in
two independent cohorts from the TCGA database. To in-
vestigate the mechanism of PXR-induced L-OHP resist-
ance, MRP3 expression was assessed in cell models that
differentially expressed PXR. The results revealed increased
MRP3 expression in PXR over-expressing cells. Luciferase
reporter and ChIP assays indicated that PXR can bind to
the promoter of MRP3 to activate transcription and fur-
thermore, that the PXR-binding sites are located at be-
tween -796 to -782bp of the MRP3 promoter. Moreover,
we found that PXR expression is an independent predictor
for poor prognosis in CRC patients. These results suggest
that PXR can transcriptionally activate MRP3 by directly
binding to its promoter, increasing drug efflux capacity and
resulting in resistance to platinum drugs.
Chemotherapy is the treatment of choice in patients
with advanced or metastatic CRC. Chemotherapeutic re-
sistance of tumor cells is crucial problem and a compli-
cated process that involves multiple genes and steps. PXR
is a member of the ligand-activated transcription factor
superfamily, and its downstream target genes are involved
in drug metabolism and transportation [20, 31]. Increasing
evidence suggests that high PXR expression is associated
with decreased treatment efficacy and increased chemo-
resistance against drug-based cancer treatments, including
Fig. 7 PXR expression is significantly associated with poor overall survival in colorectal cancer patients. a Kaplan-Meier (univariate) and Cox regression
(multivariate) survival analysis of PXR expression in 93 colorectal cancer patients. PXR expression is associated with poor OS and an independent
prognostic factor in colorectal cancer patients. Low, staining weak (≤8); High, staining strong (>8). b Kaplan-Meier and Cox regression survival
analysis of PXR expression in 47 male colorectal cancer patients. c Kaplan-Meier and Cox regression survival analysis of PXR expression in 56 stage I + II
colorectal cancer patients
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irinotecan, tamoxifen, paclitaxel, doxorubicin and vin-
blastine [32–39]. In this study, PXR increased the drug ef-
flux capacity and reduced the amount of drug in tumor
cells, attenuating the efficacy of L-OHP. PXR expression
significantly decreased L-OHP.-mediated tumour cell
growth inhibition and inducing of apoptosis. In our nude
mouse experiments, PXR decreased L-OHP-mediated
suppression of tumor growth. These results demonstrate
that PXR enhances the resistance of CRC cells to the che-
motherapeutic agent L-OHP.
Previous studies have indicated that PXR regulates a
number of genes associated with drug resistance, such as
cytochrome P450, multidrug resistance 1 and multidrug
resistance‑associated protein 2 [20, 31, 40]. Mounting
evidence has shown that PXR is a master regulator of
chemotherapeutic drug resistance in cancer treatment.
However, the specific mechanism underlying this resist-
ance remains unclear. MRP3 (also called ABCC3) be-
longs to the ABCC subfamily, which consists of 13
members in mammals and has been divided into the fol-
lowing 3 classes: the multi-drug resistance proteins
(MRPs), the sulfonylurea receptors and the cystic fibrosis
transmembrane conductance regulator (CFTR/ABCC7).
MRP3 has not been extensively studied and its function
and regulation remain to be completely established.
Moreover, MRP3 is known to transport various bile salts
and clinical drugs [41–44]. In this study, our results re-
vealed a positive correlation between MRP3 and PXR
expression (P = 0.0023), and in three independent co-
hort, we found increased MRP3 expression in samples
expressing high levels of exogenous and endogenous
PXR. As PXR is a transcription factor, we used luciferase
reporter assays to assess whether PXR binds to the
MRP3 promoter to activate its transcription. Our results
revealed that PXR can directly bind to the MRP3
promoter to activate its transcription. To determine the
precise PXR-binding site within the MRP3 promoter, we
constructed luciferase constructs containing different re-
gions of the MRP3 promoter. Luciferase reporter and
ChIP assays determined that the PXR-binding sites are
located between -884 to -620bp of the MRP3 promoter.
Further studies reveal that the key binding sites are
“———————AGGGA-” (-787 to -783bp) between
-884 to -620bp of the MRP3 promoter. These data
showed that PXR activates MRP3 transcription by dir-
ectly binding to its promoter, which increases the drug
efflux capacity and results in resistance to platinum
drugs. Unfortunately, the crucial sites within the PXR to
bind MRP3 promoter are still unknown, and further
studies employing site-directed mutagenesis of putative
binding sites in PXR are required to clarify this issue. In
addition, we also tested other known PXR target genes,
and found that the MRP5, MDR1 and OATP-A expres-
sion were slightly up-regulated in the PXR over-
expression cells (Additional file 1: Figure S1). Although
the other target genes also appeared increasing, we still
think that PXR increases the drug efflux capacity at least
in part by directly activating MRP3 transcription accord-
ing to our data of function, mechanism and restoring
experiments.
To further determine the importance of PXR in CRC,
a correlation analysis between PXR expression and the
OS of patients was performed. Kaplan-Meier and Cox-
regression analysis revealed significantly reduced OS of
patients with high PXR expression. Further studies dem-
onstrate that PXR is an unfavorable and independent
prognostic factor for male or clinical stage I + II CRC pa-
tients. These results indicate that PXR is a potential bio-
marker for predicting outcome in CRC patients.
Conclusion
In conclusion, PXR enhances the resistance of tumor cells
to the chemotherapeutic agent L-OHP via direct tran-
scriptional activating MRP3 expression, increasing the L-
OHP efflux capacity of CRC cells (Fig. 8). However,
whether this mechanism is generally applicable to all che-
motherapeutic drugs, to only specific platinum-based
drugs, or only to L-OHP requires further investigation.
Fig. 8 A schematic diagram for the mechanisms underlying PXR-
regulated MRP3-mediated resistance. PXR enhances the resistance of
tumor cells to the chemotherapeutic agent L-OHP via direct tran-
scriptional activating MRP3 expression, increasing the L-OHP efflux
capacity of tumor cells in CRC
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